Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for SARS-COV-2 Induced Pneumonia
NCT04422678Phase 3Unknown
- Sponsor
- Alexandria University
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of imatinib in COVID-19 pneumonia (3 arms), sponsored by Alexandria University. Primary endpoint: Disease Progression at 30 days. Status: unknown.
02
Drugs
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04422678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422678.